14 results about "Donepezil Hydrochloride" patented technology

The invention discloses a donepezil and memantine compound sustained release preparation and a preparation process thereof, and belongs to the technical field of pharmaceutical preparations. The preparation consists of a donepezil hydrochloride quick-release layer and a memantine hydrochloride slow-release layer, wherein the quick-release layer comprises donepezil, starch, mannitol and the like, and realizes quick disintegration through granulation of a low-substituted hydroxypropyl cellulose aqueous solution; the slow-release layer comprises memantine, pinoresinol diglucoside, a polylactic acid-glycolic acid copolymer and chitosan, and the slow-release layer and the composite slow-release material have a synergistic effect through a low-temperature grinding technology, so that the degradation of the memantine is inhibited, and the sustained release of the memantine is controlled. The problem that an existing compound preparation is poor in stability is solved, and a safe and effective treatment choice which is taken once a day is provided for a patient suffering from the Alzheimer disease.

The invention discloses a transdermal drug delivery patch with a five-layer structure and application thereof, and belongs to the technical field of pharmaceutical preparations. The patch comprises a backing film, a donepezil hydrochloride-containing reservoir layer, a controlled release film, an organic alkali-containing adhesion layer and a release film. The release rate of the donepezil hydrochloride is controlled through the controlled release film, the donepezil hydrochloride is isolated from organic alkali, the drug stability is improved, the drug release rate is regulated and controlled, the donepezil hydrochloride passes through the controlled release film and then is subjected to an in-situ reaction with the organic alkali in the adhesion layer, and the donepezil hydrochloride is converted into donepezil free alkali for transdermal delivery. According to the patch, the drug stability is improved, the preparation process is simple, the local safety is high, and the transdermal permeability of donepezil can be remarkably improved.

The present invention provides an oral dispersible film for donepezil hydrochloride. The film is a bilayer structure containing a drug layer containing 45-75% w / w donepezil hydrochloride and a backing layer without donepezil hydrochloride. The present oral film retains donepezil hydrochloride in a crystal form and minimizes impurity generation. The oral film contains a selected hydrophobic material to improve the drug stability and minimize the drug solubility.

The utility model discloses a kind of donepezil hydrochloride tablets equivalent progressive addition mixing devices, it is related to pharmaceutical technical field, including fixed cylinder, the side of fixed cylinder is provided with the feeding mechanism for feeding, the top of fixed cylinder is fixedly connected with feeding pipe and is penetrated, the inside of fixed cylinder is provided with the stirring mechanism for mixing, the inner wall of fixed cylinder is slidably connected with mixing bucket one and mixing bucket two, the inner wall of fixed cylinder bottom end is fixedly connected with mixing bucket three, the bottom of mixing bucket one, mixing bucket two and mixing bucket three is all provided with the unloading mechanism for opening and closing, the side of mixing bucket one and mixing bucket two is all fixedly connected with fixed block, the bottom of fixed block is fixedly connected with spring and telescopic rod, solved if it is through the method of adding batch quantity to mix, not only time-consuming and laborious, while opening and closing feeding pipe every time, it will increase the risk of introducing foreign contamination source in the process of mixing drug, possibly affect the finished drug quality problem.

The present invention relates to the technical field of pharmaceutical compositions, and in particular to a pharmaceutical composition for treating Alzheimer's disease and a preparation method thereof. Specifically, it is prepared from the following components by mass: 0.4-0.8 parts of butylphthalide, 0.3-0.7 parts of donepezil hydrochloride, 22-26 parts of ginkgo flavonoids, 30-40 parts of ginsenosides, 16-20 parts of gastrodia elata extract, 13-17 parts of codonopsis pilosula extract, 16-20 parts of raw dragon bone extract, 12-16 parts of calamus tatarinowii extract, 11-15 parts of astragalus extract, 10-16 parts of rhizoma anemarrhenae extract and 15-19 parts of trumpet creeper extract. The pharmaceutical composition provided by the present invention has an excellent effect in treating Alzheimer's disease, can cure patients with early Alzheimer's disease, can effectively alleviate their symptoms and prolong the life of patients with late Alzheimer's disease, and its therapeutic effect is significantly better than that of existing drugs.

The present disclosure is directed to the treatment of Alzheimer's disease by administering 1′,3′-dihydro-2H-spiro[imidazo[1,2α]pyridine-3,2′-inden]-2-one orally at a daily dose of 180 mg as a single active agent or co-administered with donepezil hydrochloride and / or memantine hydrochloride.

The present invention discloses a stable crystalline form of donepezil hydrochloride orally disintegrating film and a preparation method thereof, comprising: a drug-loading layer and a film-coating layer; the raw materials of the drug-loading layer include: crystalline donepezil hydrochloride and a first film-forming substance; wherein, the raw materials of the drug-loading layer are mixed evenly with a first organic solvent to obtain a drug-loading layer solution, and a film is formed to obtain the drug-loading layer; the water content of the first organic solvent is ≤ 0.5%. The preparation method of the orally disintegrating film comprises the following steps: mixing the raw materials of the drug-loading layer with a first organic solvent to obtain a drug-loading layer solution; coating the drug-loading layer solution on the surface of the film-coating layer and drying to obtain the donepezil hydrochloride orally disintegrating film. The present invention can maintain the stability of the crystalline form of donepezil hydrochloride, without the problem of crystal transformation, while improving the stability of the orally disintegrating film; and has a good taste and bioavailability.

To suppress bitter taste of a pharmaceutically active compound while suppressing cost without requiring a complicated process and a plurality of additives.SOLUTION: The present invention provides a bitterness suppressor for a pharmaceutically active compound, comprising a cyclodextrin and / or a derivative thereof as an active ingredient, wherein the pharmaceutically active compound is any one selected from the group consisting of duloxetine hydrochloride, aripiprazole, atomoxetine hydrochloride, donepezil hydrochloride, and dorzolamide hydrochloride.SELECTED DRAWING: None

To suppress bitter taste of a pharmaceutically active compound while suppressing cost without requiring a complicated process and a plurality of additives.SOLUTION: The present invention provides a bitterness suppressor for a pharmaceutically active compound, comprising a cyclodextrin and / or a derivative thereof as an active ingredient, wherein the pharmaceutically active compound is any one selected from the group consisting of duloxetine hydrochloride, aripiprazole, atomoxetine hydrochloride, donepezil hydrochloride, and dorzolamide hydrochloride.SELECTED DRAWING: None

To suppress bitter taste of a pharmaceutically active compound while suppressing cost without requiring a complicated process and a plurality of additives.SOLUTION: The present invention provides a bitterness suppressor for a pharmaceutically active compound, comprising a cyclodextrin and / or a derivative thereof as an active ingredient, wherein the pharmaceutically active compound is any one selected from the group consisting of duloxetine hydrochloride, aripiprazole, atomoxetine hydrochloride, donepezil hydrochloride, and dorzolamide hydrochloride.SELECTED DRAWING: None

The invention discloses a method for determining the content of a memantine hydrochloride and donepezil preparation, and the preparation of a sample solution during detection specifically comprises the following steps: taking the content or reference substance of the memantine hydrochloride and donepezil preparation, dissolving the content or reference substance with a nitrile-inorganic solvent, and diluting the dissolved solution with a triethylamine mixed solution until each 1ml of the solution contains 0.5-1000 [mu] g of memantine hydrochloride and 0.5-1000 [mu] g of donepezil hydrochloride. According to the method, the content of the preparation does not need to be ground into powder through the specific solvent, a sample is prevented from being polluted, the content of the medicinal components memantine hydrochloride and donepezil hydrochloride in the prepared sample solution can be accurately and quantitatively determined through the specific liquid chromatography condition, the detection time is short, the medicinal components can be detected at the same time within 15 min, and the detection cost is low; the method is convenient, strong in specificity, high in accuracy, high in recovery rate and strong in applicability, and has practical popularization and application values.

The invention relates to a 3D tissue scaffold containing the active pharmaceutical ingredients, memantine hydrochloride and donepezil hydrochloride, and a method of production of this tissue scaffold. Said scaffold accelerates bone repair thanks to the active pharmaceutical ingredients contained therein and a 3D porous structure.

The invention discloses a donepezil long-acting transdermal patch and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The limitation of low fat-soluble transdermal delivery rate of an ionic drug is broken through through a salt-alkali in-situ transformation mechanism, the permeation flux is improved, meanwhile, long-time lasting slow release and transdermal delivery are realized through cooperative regulation and control of a controlled release membrane and a chemical transformation reaction, and the sustained release stability and transdermal high efficiency are both realized; through the interlayer isolation design, the influence on the stability of the medicinal preparation caused by mixing and dissolving of donepezil hydrochloride and alkaline components in the storage process of the medicinal preparation is avoided. The release rate is regulated and controlled through the controlled release film, so that the donepezil hydrochloride and the organic alkali in the adhesive layer are subjected to in-situ chemical reaction and are converted into donepezil free alkali with high fat solubility, thereby breaking through cuticle barrier limitation and achieving long-time steady-state percutaneous delivery of donepezil. The preparation method is easy to operate and has the advantages of being high in process universality, good in quality control, wide in application range and the like.

The present invention provides an oral dispersible film for donepezil hydrochloride. The film is a bilayer structure containing a drug layer containing 45-75% w / w donepezil hydrochloride and a backing layer without donepezil hydrochloride. The present oral film retains donepezil hydrochloride in a crystal form and minimizes impurity generation. The oral film contains a selected hydrophobic material to improve the drug stability and minimize the drug solubility.